Takeda Febuxostat Benefits Outweigh CV Risk; Will Other Gout Drugs Follow?

Strong efficacy data and a desperate need for new gout therapies outweigh the potential cardiovascular risk associated with Takeda's febuxostat, an FDA advisory committee determined in recommending approval of the drug during a Nov. 24 meeting